Dr. Bryan Townsend

Dr. Bryan Townsend operates U. S. Dermatology Partners in Austin, specializing in Mohs Micrographic Surgery for skin cancer treatment and offering various skin rejuvenation services to enhance patient health and aesthetics.

Founded in 1998 and based in Austin, US, Dr. Bryan Townsend’s practice focuses on dermatological care with a special emphasis on Mohs Micrographic Surgery. The company has executed a deal in January 2017, when Dermatology Associates of Tyler, a portfolio company of ABRY Partners, acquired Dr. Bryan Townsend.

The founder, Dr. Bryan Townsend, has a history in dermatology, with previous experience in establishing practices that prioritize patient care. U. S.

Dermatology Partners, functioning under the brand Mohs Surgeon in Austin, provides expert treatment for skin cancers through Mohs Micrographic Surgery. This method is highly effective in removing cancerous tissues while preserving healthy skin, ensuring optimal aesthetic results. The practice also offers non-surgical skin rejuvenation options, such as microneedling and laser therapies, catering primarily to residents in the North Austin – Domain area, including students from the University of Texas. The revenue at U.

S. Dermatology Partners comes primarily from patient interactions seeking specialized dermatological care. The firm uses a transactional model where patients are billed for services, with surgical procedures typically covered by insurance and cosmetic treatments paid out-of-pocket. Mohs surgery significantly contributes to revenue due to its specialized nature and demand among skin cancer patients.

Additional revenue streams include consultations and non-invasive procedures, maintaining a focus on quality patient care. Following its acquisition in January 2017, Dr. Bryan Townsend plans to leverage its resources to enhance service offerings and expand market reach. The practice aims to introduce new skin health products and expand into additional geographic regions.

Utilizing insights from recent operational consolidations, it seeks to strengthen its presence particularly in areas with high incidences of skin cancer, focusing on tailored marketing strategies and service diversification to meet growing patient needs.